[[(2S)-2-[(1R)-1-(6-aminopurin-9-yl)-2-hydroxyethoxy]-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-N-[[[(2S)-2-[(1R)-1-(6-aminopurin-9-yl)-2-hydroxyethoxy]-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]phosphonamidic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: [[(2S)-2-[(1R)-1-(6-aminopurin-9-yl)-2-hydroxyethoxy]-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-N-[[[(2S)-2-[(1R)-1-(6-aminopurin-9-yl)-2-hydroxyethoxy]-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-hydroxyphosphoryl]phosphonamidic acid
• 化学式: C₂₀H₃₃N₁₁O₁₈P₄
• 分子量: 839.4
• InChiKey: AOQQBVGUMMONMS-IGQOVBAYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.4
• 重原子数：
  53
• 可旋转键数：
  22
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  437
• 氢给体数：
  11
• 氢受体数：
  27

文献信息

• DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN
  申请人：GlobalAcorn Ltd.

  公开号：US20150119352A1

  公开（公告）日：2015-04-30

  The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use in the inhibition (or down-regulation) of a pain, via a transducing ATP-gated P2X3 receptor, often by means of high-affinity desensitisation (HAD) mechanism.
• COMPOSITIONS
  申请人：GLOBALACORN LTD

  公开号：US20160354402A1

  公开（公告）日：2016-12-08

  The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use as an anticonvulsant and/or seizure suppressant, in particular in the treatment or prevention of (e.g. juvenile) epilepsy.
• [EN] DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN<br/>[FR] DINUCLÉOSIDE POLYPHOSPHATES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：GLOBALACORN LTD

  公开号：WO2013175231A1

  公开（公告）日：2013-11-28

  The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use in the inhibition (or down-regulation) of a pain, via a transducing ATP -gated P2X3 receptor, often by means of high-affinity desensitisation (HAD) mechanism.
• [EN] COMPOSITIONS<br/>[FR] COMPOSITIONS
  申请人：GLOBALACORN LTD

  公开号：WO2015079240A1

  公开（公告）日：2015-06-04

  The present invention relates to administration of a dinucleoside polyphosphate analogue or a pharmaceutically acceptable salt thereof, topically in a formulation comprising a suitable excipient or using a device for transdermal delivery, and/or combined with a nanoparticle carrier. The present invention also relates to the therapeutic use of such compositions or devices, in particular in the treatment of painor epilepsy. The analogue may be combined with an anaesthetic (such as a salt form) or delivered in a nanoparticle.